SavedAdd your journal

Journals / European Archives of Medical Research / 2019 / Cilt: 35 - Sayı: 3

Evaluation of Echocardiographic Findings of Mucopolysaccharidosis Cases

Nafiye Emel ÇAKAR
Meryem KARACA
Pages
167–169
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For all these reasons, cardiac evaluation in MPS patients should be performed at least once a year with accompanying electrocardiogram andechocardiography.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Mucopolysaccharidosis (MPS) is a lysosomal storage disease in which the degradation of glycosaminoglycans is impaired.
📊
Key Findings & Data:In this study, we aimed to evaluate the echocardiographic reports of our patients with MPS retrospectively.Methods: Echocardiography reports of 37 patients with MPS were reviewed retrospectively.Results: Cardiac involvement was present in 70.2% our patients and the most commonly involved structure was mitral valve (59.5%).
💡
Conclusion & Impact:For all these reasons, cardiac evaluation in MPS patients should be performed at least once a year with accompanying electrocardiogram andechocardiography.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Mucopolysaccharidosis (MPS) is a lysosomal storage disease in which the degradation of glycosaminoglycans is impaired. Cardiac involvement may occur indifferent ways in all types of the disease. In this study, we aimed to evaluate the echocardiographic reports of our patients with MPS retrospectively.Methods: Echocardiography reports of 37 patients with MPS were reviewed retrospectively.Results: Cardiac involvement was present in 70.2% our patients and the most commonly involved structure was mitral valve (59.5%). The most common pathology inmitral valve was mitral valve regurgitation (51.4%).Conclusion: Cardiac involvement and complications are frequently seen in MPS. Heart failure, coronary artery involvement and arrhythmias are the main causes ofdeath. Early diagnosis of MPS and early initiation of enzyme replacement therapy may improve cardiac involvement. Progressive valve involvement may require surgicalintervention over time. For all these reasons, cardiac evaluation in MPS patients should be performed at least once a year with accompanying electrocardiogram andechocardiography.

🔖

Cite This Article

ÇAKAR, N. E., KARACA, M. (2022). Evaluation of Echocardiographic Findings of Mucopolysaccharidosis Cases. European Archives of Medical Research, Cilt: 35 - Sayı: 3, 167–169. https://ajindex.com/articles/510414

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Stapleton M, Arunkumar N, Kubaski F, Mason RW, Tadao O, Tomatsu S. Clinical presentation and diagnosis of mucopolysaccharidoses. Mol Genet Metab 2018;125:4-17
  2. Fernandes J, Saudubray J-M, Berghe G van den, Walter JH, editors. Inborn Metabolic Diseases: Diagnosis and Treatment. 4th ed. Berlin Heidelberg: Springer-Verlag 2006:580-3
  3. Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders--clinical and echocardiographic findings in 64 patients. Eur J Pediatr 1998;157:534-8
  4. Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis 2011;34:1183-97
  5. Mohan UR, Hay AA, Cleary MA, Wraith JE, Patel RG. Cardiovascular changes in children with mucopolysaccharide disorders. Acta Paediatr 2002;91:799- 804
  6. Leal GN, de Paula AC, Leone C, Kim CA. Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young 2010;20:254-61
  7. Moog U, van Mierlo I, van Schrojenstein Lantman-de Valk HMJ, Spaapen L, Maaskant MA, Curfs LMG. Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems? Am J Med Genet C Semin Med Genet 2007 15;145:293-301
  8. Braunlin EA, Berry JM, Whitley CB. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 2006;98:416-8
  9. Fesslová V, Corti P, Sersale G, Rovelli A, Russo P, Mannarino S, et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 2009;19:170-8.